Depression and anxiety in a Portuguese MS population: Associations with physical disability and severity of disease

Journal of the Neurological Sciences

Volumn 306, Issue 1-2, 2011, Pages 66-70

  Da Silva, Ana Martins ^a,b   Vilhena, Estela ^c   Lopes, Alice ^a   Santos, Ernestina ^a,b   Gonçalves, Maria Alexandra ^a   Pinto, Cláudia ^a   Moreira, Inês ^a   Mendonça, Denisa ^b   Cavaco, Sara ^a,b,d  

^a HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c Instituto Politcnico do Cvado e do Ave   (Portugal)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

Anxiety; Depression; Disability status; Hospital Anxiety and Depression Scale; Multiple sclerosis; Severity

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BETA INTERFERON; PSYCHOTROPIC AGENT;

ADULT; AGE; ANXIETY DISORDER; CONFERENCE PAPER; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; EDUCATIONAL STATUS; EXPANDED DISABILITY STATUS SCALE; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PHYSICAL DISABILITY; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; SELF REPORT; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; ANXIETY; DEPRESSION; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PORTUGAL; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 79958771571     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2011.03.042     Document Type: Conference Paper

References (47)

1. Thompson AJ. Multiple sclerosis - a global disorder and still poorly managed. Lancet Neurol 2008;7:1078-9.
2. Patten SB, Beck CA, Williams JV, Barbui C, Metz LM. Major depression in multiple sclerosis: a population-based perspective. Neurology 2003;61:1524-7. (Pubitemid 37505573)
3. Joffe RT, Lippert GP, Gray TA, Sawa G, Horvath A. Mood disorders and multiple sclerosis. Arch Neurol 1987;44:376-8.
4. Whitlock FA, Siskind MM. Depression as a major symptom of multiple sclerosis. J Neurol Neurosurg Psychiatry 1980;43:861-5. (Pubitemid 11250728)
5. Ziemssen T. Multiple sclerosis beyond EDSS: depression and fatigue. J Neurol Sci 2009;277:S37-41.
6. Patten SB, Metz LM, Reimer MM. Biopsychosocial correlates of major depression in a multiple sclerosis population. Mult Scler 2000;6:115-20. (Pubitemid 30218905)
7. Sadovnik AD, Remick RA, Allen J, Swartz E, Yee IML, Eisen K, et al. Depression and multiple sclerosis. Neurology 1996;46:628-32. (Pubitemid 26099623)
8. Lobentanz IS, Asenbaum S, Vass K, Sauter C, Klosh G, Kollegger H, et al. Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality. Acta Neurol Scand 2004;110:6-13. (Pubitemid 38850550)
9. Benedict RHB, Wahlig E, Bakshi R, Fishman I, Munschauer F, Zidadinov R, et al. Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behaviour change. J Neurol Sci 2005;231:29-34. (Pubitemid 40432023)
10. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon B-1b therapy for multiple sclerosis. Arch Neurol 1997;54:531-3. (Pubitemid 27204238)
11. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991;41:1193-6.
12. Stenager EN, Stenager E, Koch-Henriksen N, Bronnum-Hansen H, Hyllested K, Jensen K, et al. Suicide and multiple sclerosis: an epidemiological investigation. J Neurol Neurosurg Psychiatry 1992;55:542-5.
13. Charcot JM. Lectures on the diseases of nervous system. Philadelphia: Henry C Lea; 1879.
14. Dalton EJ, Heinrichs RW. Depression in multiple sclerosis: a quantitative review of the evidence. Neuropsychology 2005;19:152-8. (Pubitemid 40381651)
15. Honarmand K, Feinstein A. Validation of the Hospital Anxiety and Depression Scale for use with multiple sclerosis patients. Mult Scler 2009;15:1518-24.
16. Zigmond AP, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-70. (Pubitemid 13098606)
17. Zorzon M, Masi R, Nasuelli M, Ukmar M, Mucelli RP, Cazzato G, et al. Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. J Neurol 2001;248:416-21. (Pubitemid 32477335)
18. Dahl O, Stordal E, Lydersen S, Midgard R. Anxiety and depression inmultiple sclerosis. Acomparative population-based study in Nord-Trondelag County, Norway. Mult Scler 2009;15:1495-501.
19. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002;52:69-77. (Pubitemid 34192886)
20. Silverstone PH. Prevalence of psychiatric disorders in medical patients. J Nerv Ment Dis 1996;184:43-51. (Pubitemid 26050312)
21. Johnson G, Burvill PW, Anderson CS, Jamrozik K, Steartwynne EG, Chakera TMH. Screening instruments for depression and anxiety after stroke - experience in the Perth Community Stroke Study. Acta Psychiatr Scand 1995;91:252-7.
22. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "Mc Donald Criteria". Ann Neurol 2005;58:840-6.
23. Grupo de Estudos de Envelhecimento Cerebral e Demência. Escalas e testes na demência2nd Ed. Lisboa: GEECD; 2008.
24. Pais-Ribeiro J, Silva I, Ferreira T, Martins A, Meneses R, Baltar M. Validation study of a Portuguese version of the Hospital Anxiety and Depression Scale. Psychol Health Med 2007;12:225-35.
25. Kurtke JF. Neurologic impairment in multiple sclerosis and disability status scale. Acta Neurol Scand 1970;46(4):493-512.
26. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, et al. Multiple sclerosis severity score. Using disability and disease duration to rate disease severity. Neurology 2005;64:1144-51.
27. Mykletun A, Stordal E, Dahl AA. Hospital Anxiety and Depression (HAD) scale: factor structure, item analyses and internal consistency in a large population. Br J Psychiatry 2001;179:540-4. (Pubitemid 34031681)
28. Galeazzi GM, Ferrari S, Giaroli G, Mackinnon A, Merelli E, Motti L, et al. Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy. Neurol Sci 2005;26:255-62. (Pubitemid 41447824)
29. Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler 2007;13:67-72. (Pubitemid 46152763)
30. Gay MC, Vrignaud P, Garitte C, Meunier C. Predictors of depression in multiple sclerosis patients. Acta Neurol Scand 2010;121(3):161-70.
31. McIvor GP, Riklan M, Reznikoff M. Depression as a function of length and severity of illness, age, remission and perceived social support. J Clin Psychol 1984;40:1028-33. (Pubitemid 14061564)
32. Sanfilipo MP, Benedict RHB, Weinstock-Guttman B, Bakshi R. Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology 2006;66:685-92. (Pubitemid 43739822)
33. Siegert RJ, Abernethy DA. Depression and multiple sclerosis: a review. J Neurol Neurosurg Psychiatry 2005;76:469-75.
34. Sá MJ. Psychological aspects of multiple sclerosis. Clin Neurol Neurosurg 2008;110:868-77.
35. Berg D, Supprian T, Thomae J, Warmuth-Metz M, Horowski A, Zeiler B, et al. Lesion pattern in patients with multiple sclerosis and depression. Mult Scler 2000;6:156-62.
36. Mohr DC, Epstein L, Luks TL, Goodkin D, Cox D, Goldberg A, et al. Brain lesion volume and neuropsychological function predict efficacy of treatment for depression in multiple sclerosis. J Consult Clin Psychol 2003;71:1017-24. (Pubitemid 37448892)
37. Feinstein A, O'Connor P, Akbar N, Moradzadeh L, Scott CJ, Lobaugh NJ. Diffusion tensor imaging abnormalities in depressed multiple sclerosis patients. Mult Scler 2010;16:189-96.
38. Feinstein A, Roy P, Lobaugh N, Feinstein K, O'Connor P, Black S. Structural brain abnormalities inmultiple sclerosis patients inmajor depression. Neurology 2004;62:586-90. (Pubitemid 38252800)
39. Muller SG, Mack WJ, Dungas A, Kramer JH, Cardenas-Nicolson V, Lavrestky H, et al. Influences of lobar gray matter and white matter lesion load on cognition and mood. Psychiatry Res 2010;181:90-6.
40. Kern S, Ziemssen. Brain-immune communication psychoneuroimmunology. Mult Scler 2008;14:6-21.
41. Raison CL, Capuron L, Miller AH. Cytokines sing the blues. Inflammation and pathogenesis of depression. Trends Immunol 2006;27:24-31.
42. Julian LJ. ApoE alleles, depression and positive affect in multiple sclerosis. Mult Scler 2009;15:311-5.
43. Goeb JL, Even C, Nicolas G, Gohier B, Dubas F, Garré JB. Psychiatric side effects of interferon-B in multiple sclerosis. Eur Psychiatry 2006;21:186-93.
44. Patten SB, Fridhandler S, Beck CA, Metz LM. Depressive symptoms in a treated multiple sclerosis cohort. Mult Scler 2003;9:616-20. (Pubitemid 37479412)
45. Zephir H, De Seze J, Stojkovic T, Delisse B, Ferriby D, Cabaret M, et al. Multiple sclerosis and depression: influence of interferon beta therapy. Mult Scler 2003;9:284-8. (Pubitemid 36681895)
46. Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: the national comorbidity survey. Am J Psychiatry 1994;151:979-86. (Pubitemid 24208631)
47. Bjerkeset O, Nordahl HM, Larsson S, Dahl AA, Linaker O. A 4-year follow-up study of syndromal and sub-syndromal anxiety and depression symptoms in the general population. Soc Psychiatry Psychiatr Epidemiol 2008;43:192-9.